Teleflex (TFX) Q3 2026 earnings review
Teleflex raises its profit outlook, but its sales growth slows
Teleflex is turning the money from businesses it sold into debt repayment and share buybacks, while its sales stood still. Sales from businesses it owned a year ago grew 3% excluding currency, and profit per share excluding one-offs jumped by more than a third. A refund of tariffs Teleflex had already paid supplied much of that, and Weidman still raised the full-year earnings plan.
| Sales from businesses it owned a year ago, excluding currency | +3.0% +4.7% last quarter |
|---|---|
| Profit per share, excluding one-offs | $2.63 $1.89 a year ago |
| The same, excluding the tariff refund | about $2.32 +23% a year ago, by our math |
| Full-year profit outlook, excluding one-offs | Raised to $7.50–$7.75 $6.90–$7.20 in August |
⚖️ Verdict: 🟢 Bullish
The story got better, because Teleflex turned the cash from its OEM sale into less debt and a smaller share count. It repaid a $700 million loan and bought $350 million of stock since July. One caution: the tariff refund supplied most of the margin gain.
The question now is whether Interventional can grow as fast as its market once the integration ends. Weidman calls these "mid-single-digit markets"; the other answer is that the acquired portfolio is simply a slow-growing asset. Its fourth-quarter growth rate, and the 2027 plan due on the next call, will settle it.
🐂 Bull Case
Buybacks And Debt Paydown Lift Earnings
Teleflex sold its OEM unit for $1.5 billion in cash in August and promised the money to lenders and shareholders. Finance chief John Deren moved fast, repaying a $700 million term loan and cutting borrowings on the revolving credit line.
Since the start of July the medical device maker has repurchased $350 million of stock, which Deren called "ahead of our expectations". That was 2.7 million shares at an average price of $128.96, and it was quicker than the plan he set out in August.
- Shares used to divide profit: 41.6 million, from 44.2 million a year ago
- Interest cost, net of interest earned: $18.9 million, against $30.0 million
- Borrowings: $1.6 billion, down 39% since December
- Debt against profit: about 1.4 times, from 2.8 times in June
Fewer shares and a smaller interest bill, not sales, carried the profit: earnings per share excluding one-offs rose 39% while revenue stood still. Deren has $400 million of the authorisation left and will not use it until the Acute Care sale closes.
What to watch: whether that sale to Intersurgical closes in December, as Weidman intends. A slip pushes back the last $400 million of buying and the service fees meant to cover costs the divestitures leave behind.
Two Of Three Businesses Grow Near 5%
Vascular sells the tubes and needles that get fluids and drugs into a patient's bloodstream; Surgical sells instruments such as ligation clips and skin staplers. Together they are nearly two-thirds of sales, and each grew about 5% once currency is stripped out.
Growth in Vascular came from its "intraosseous portfolio, hemostatic products and peripheral access products", Weidman said, while Surgical leaned on "strong performances in ligation clips and skin stapling". Both rates fell from the first half, which Teleflex had flagged: distributors are working down stock built after a lidocaine recall.
What to watch: Vascular's growth rate in the fourth quarter, once that destocking ends. Near 5% rather than the 8% of the spring would make mid-single-digit markets the ceiling for the whole group.
Positives this quarter didn't test
Three parts of the bull case got news this quarter but no revenue to test it. Each of them lands in 2027 or later, which is also when Weidman has promised figures for the first time.
- EZPLAZ, "the first and only FDA-licensed freeze-dried plasma": Weidman now sees a "potential long-term U.S. market opportunity of at least $200 million", with no sales this year.
- Freesolve, a heart-artery scaffold that dissolves over months: it "received FDA Breakthrough Device Designation for PCI", and the first randomised results arrive late in 2027.
- Next year's earnings: "a meaningful step-up in adjusted earnings per share in 2027", with no number attached to it yet.
What to watch: the 2027 outlook Weidman has promised for the next call. A figure for EZPLAZ, or for the step-up in earnings, would turn three statements of intent into something a reader can check.
🐻 Bear Case
A Tariff Refund Supplied The Margin Gain
In February the Supreme Court struck down tariffs imposed under emergency powers, so Teleflex asked for its money back. Refunds of $39.2 million arrived this quarter, and $25.3 million fell in the businesses it keeps, cutting the cost of making products.
Weidman called the quarter one of "margin expansion and robust earnings per share growth, even when excluding IEEPA tariff refunds". Deren traced 2.9 of the 4.5-point rise in gross margin to the refund. Strip the money out and operating profit hardly moves, because selling and administrative costs took more of each sales dollar.
- Gross margin: 66.8% of sales, from 62.3% a year ago
- Selling and administrative costs: 34.3% of sales, from 32.7%
- Operating profit margin excluding the refund: about 22.1%, against 22.0%, by our math
Teleflex still pays tariffs. Deren expects "approximately a little over $30 million" again next year, and he has no arrangement with Washington of the sort a larger rival struck this autumn.
What to watch: the operating profit margin in the fourth quarter. By our math the full-year plan leaves about 17%, against 21.5% a year earlier, because Deren is funding a trial: "we do have a significant step-up planned in R&D expense".
Interventional Returned To Growth, Barely
Interventional sells catheters, stents and the devices doctors use to open blocked blood vessels, and it holds the Vascular Intervention business Teleflex bought from BIOTRONIK. Sales there shrank 1% in the spring quarter. This time they edged up 0.2% once currency is stripped out.
Weidman described repair work rather than demand, and conceded that "the VI portion has performed worse than the legacy business because this is integration disruption related".
- Customers moved onto Teleflex's ordering system: about 90%
- Misdirected orders in Europe: 7% in the spring, below 1% leaving September
- Indirect business now run through Teleflex distributors: 87%
- Open sales territories: "openings down 63% from their peak"
One quarter at 0.2% does not settle a worry that has run since the spring, because the representatives hired for those territories are not selling much yet: "it takes, on average, 6 months for reps to get productive," Weidman said. He is targeting "a modest sequential improvement" in the fourth quarter.
What to watch: Interventional's growth rate in the fourth quarter and again in the spring. Mid-single-digit growth would show the acquired portfolio works; a fourth quarter near zero would point at the products rather than the plumbing.
Risks this quarter didn't answer
Six standing worries got no new numbers this quarter. Each of them has a named place where the figure will eventually turn up.
- Acute Care sale: the antitrust review is unfinished, and "closing may extend into 2027", which holds the last $400 million of buybacks.
- Costs left behind: about $90 million a year, against "approximately $50 million in annual pretax cost savings upon completion in mid-2028".
- The 23% margin promise: repeated, still undated — "we're confident in the first 12 months on that 23% op margin".
- Next year: no figures, because Deren asked investors to "let us get through Q4".
- Freesolve: no trial results before late 2027, so its worth rests on data, not sales.
- Palette: former shareholders still claim milestone payments, with any update in the quarterly filing.
What to watch: the closing notice for the Acute Care sale and the 2027 plan due on the next call. Both carry numbers.
👓 Other Themes
Three Global Business Units Replace Regions
Teleflex used to run itself by region. From this quarter "we now manage and report as three global business units, Vascular, Interventional and Surgical", Weidman said, and Teleflex restated every earlier period on the new basis. Each unit owns its strategy and its results, which he says ends a structure where "accountability was spread across too many people". No savings figure is attached yet.
💲 Other KPIs
Receivables rose to $379.6 million from $345.6 million at the end of December, while sales stood still. Against the quarter's revenue they are back at March's level after easing in June. Teleflex is collecting more slowly than a year ago, and the switch of ordering systems in Interventional is one place to look.
Stock on hand fell 4.9% from the end of December and sits below the March and June levels. Running it down is a large part of why cash from operations reached $234.8 million over nine months, against $10.3 million a year earlier.
The rate rose from 9.3% a year ago. Deren blamed a mix of countries that worked against Teleflex, plus the cost of spreading research spending over several years for tax. Nine months in, the rate stands at 12.7%, and the company's own assumption points to a lighter fourth quarter.
🔮 Guidance
Cut, and only because of currency: Teleflex now assumes exchange rates add 0.5% to revenue instead of 0.7%. Nothing in the underlying plan moved. The range still carries the acquired stent business for the first half of 2025, which is why the reported growth figure looks so large.
Unchanged. Nine months in, Teleflex has delivered 4.2%. By our math the range leaves about 3.4% for the fourth quarter at the middle, close to this quarter's rate and below the first half. Weidman said the low end assumes Interventional does not improve on its summer level, and that he has high confidence in reaching it.
Raised. The middle of the range moved up $0.25, mostly on the tariff refunds and the smaller share count. The gap to the figure excluding one-offs is still about $4.70 a share, made up of amortisation of intangible assets, restructuring work and divestiture costs.
Raised. The middle of the range gained $0.58, to about 9% growth for the year. By our math that leaves roughly $1.90 for the fourth quarter, a little under last year's result. Deren attributed $0.31 of the year's figure to tariff refunds. It is the third increase in four statements of this number, and the latest step was slightly smaller than the one before.
Raised by a point, and the refund explains it: the $16.5 million sits inside this assumption. Nine months in, the margin is 20.9%. By our math the fourth quarter then lands near 17%, against 21.5% a year earlier. Deren pointed to start-up costs for the BIOMAG-III trial and further spending across the portfolio.
Unchanged. The quarterly bill keeps falling after August's loan repayment: $18.9 million this quarter, against $30.0 million a year earlier. Deren said next year carries the full saving, and he has not yet counted the proceeds from the Acute Care sale against debt.
Cut, which adds a few cents to the earnings plan. Teleflex has moved this assumption at each of the last three statements of it, always downwards, and gives no reason beyond the mix of countries where it earns its profit.
Cut, which here is good news. The accelerated repurchase finished, so Teleflex now assumes 42.5 million shares for the year against 43.3 million in August. The figure takes in nothing beyond the buying done by November 5, so the final $400 million of the authorisation would lower it again.
❓ Key Questions
How much will EZPLAZ sell in 2027?
Weidman sizes the American market at $200 million or more but will not put a number on next year, and says the government will take most of his capacity. Without a figure, the long-term opportunity cannot be checked.
What do the service agreements pay, and when do they end?
The fees from Intersurgical and the OEM buyer are meant to cover about $90 million of costs left behind each year. Teleflex has never published the amount per agreement or the expiry dates, and announced savings cover little more than half.
How fast does the acquired stent business grow on its own?
Weidman has declined for two quarters to separate the BIOTRONIK business from legacy Interventional, saying only that it did worse. Investors cannot tell whether the problem is the integration or the portfolio.
How much more tariff money is coming?
Teleflex says it will file more refund claims in the fourth quarter under the final phase of the process. It has not said how much it expects, which matters because the refund already drove this quarter's margin.
What growth rate will the 2027 plan commit to?
The old 6% ambition has quietly become about 4%. Weidman promised a 2027 outlook on the next call, and the growth rate he commits to will show whether the mid-term ambition has been reset again.